233 related articles for article (PubMed ID: 32687346)
1. The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions.
Radaeva M; Dong X; Cherkasov A
J Chem Inf Model; 2020 Aug; 60(8):3703-3721. PubMed ID: 32687346
[TBL] [Abstract][Full Text] [Related]
2. Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
Catanzaro E; Betari N; Arencibia JM; Montanari S; Sissi C; De Simone A; Vassura I; Santini A; Andrisano V; Tumiatti V; De Vivo M; Krysko DV; Rocchi MBL; Fimognari C; Milelli A
Eur J Med Chem; 2020 Sep; 202():112504. PubMed ID: 32712536
[TBL] [Abstract][Full Text] [Related]
3. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
[TBL] [Abstract][Full Text] [Related]
5. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
6. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs.
Baglini E; Salerno S; Barresi E; Robello M; Da Settimo F; Taliani S; Marini AM
Eur J Pharm Sci; 2021 Jan; 156():105594. PubMed ID: 33059042
[TBL] [Abstract][Full Text] [Related]
7. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
Arencibia JM; Brindani N; Franco-Ulloa S; Nigro M; Kuriappan JA; Ottonello G; Bertozzi SM; Summa M; Girotto S; Bertorelli R; Armirotti A; De Vivo M
J Med Chem; 2020 Apr; 63(7):3508-3521. PubMed ID: 32196342
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase inhibitors as anticancer agents: a patent update.
Khadka DB; Cho WJ
Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
[TBL] [Abstract][Full Text] [Related]
10. Insight into Mechanism of Action of Anticancer Benzazoles.
Ozturk O; Aki-Yalcin E; Yalcin I; Grifitth R
Curr Top Med Chem; 2020; 20(23):2056-2069. PubMed ID: 32814529
[TBL] [Abstract][Full Text] [Related]
11. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Ortega JA; Arencibia JM; Minniti E; Byl JAW; Franco-Ulloa S; Borgogno M; Genna V; Summa M; Bertozzi SM; Bertorelli R; Armirotti A; Minarini A; Sissi C; Osheroff N; De Vivo M
J Med Chem; 2020 Nov; 63(21):12873-12886. PubMed ID: 33079544
[TBL] [Abstract][Full Text] [Related]
12. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
13. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
[TBL] [Abstract][Full Text] [Related]
15. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.
Kuriappan JA; Osheroff N; De Vivo M
J Chem Inf Model; 2019 Sep; 59(9):4007-4017. PubMed ID: 31449404
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION.
Mudeppa DG; Kumar S; Kokkonda S; White J; Rathod PK
J Biol Chem; 2015 Aug; 290(33):20313-24. PubMed ID: 26055707
[TBL] [Abstract][Full Text] [Related]
17. The role and potential of computer-aided drug discovery strategies in the discovery of novel antimicrobials.
Oselusi SO; Dube P; Odugbemi AI; Akinyede KA; Ilori TL; Egieyeh E; Sibuyi NR; Meyer M; Madiehe AM; Wyckoff GJ; Egieyeh SA
Comput Biol Med; 2024 Feb; 169():107927. PubMed ID: 38184864
[TBL] [Abstract][Full Text] [Related]
18. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
[TBL] [Abstract][Full Text] [Related]
20. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]